Roche, Xofluza
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study Reducing the spread of infection in the household could help limit transmission within communities and societies,
Roche’s Xofluza reduces flu transmission in Phase 3 study
According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.
Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral.
Roche touts positive Phase III results with Xofluza
Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses.
Roche's Xofluza Reduces Influenza Transmission In Phase III Study
Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc
GlobalData on MSN5d
Roche reports positive data from Phase III influenza treatment trial
According to the findings, the antiviral treatment demonstrated to significantly reduce the transmission of influenza viruses ...
Roche unit hits main goal in late-stage trial for flu therapy
Roche (OTCQX:RHHBY) subsidiary Genentech announced on Thursday that Xofluza, an FDA-approved flu antiviral, achieved its ...
Business Wire6d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...
Morningstar6d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...
Stockhouse5d
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household ...